ATNX Athenex Inc.

14.33
-0.68  -5%
Previous Close 15.01
Open 15.02
Price To Book 7.58
Market Cap 1,108,923,539
Shares 77,384,755
Volume 561,380
Short Ratio
Av. Daily Volume 1,094,743
Stock charts supplied by TradingView

NewsSee all news

  1. Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

    The agreement covers China, Hong Kong and Macao (the "Territory") and represents an expansion of the existing relationship between the two companies. Athenex will receive payments of up to $200 million which include an

  2. Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer

    First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial Data to be presented today in an oral presentation at the 2019 San Antonio Breast

  3. Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019

    BUFFALO, N.Y., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  4. Athenex Announces $60 Million Private Placement

    BUFFALO, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  5. Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium

    Abstract selected for the SABCS press programOral presentation of Oral Paclitaxel and encequidar Phase III results on December 13Company to host a Key Opinion Leader webcast event for the investment community BUFFALO,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 preliminary data showed 50% PR and 50% SD among first 12 patients.
Oraxol
Breast cancer
Phase 1b poster at ESMO September 29, 2019.
Oraxol and CYRAMZA (Ramucirumab)
Gastric cancer
NDA filing due 1Q 2020.
Tirbanibulin ointment
Actinic keratosis
Phase 3 data noted PFS (p=0.077) 9.3 months vs 8.3 months. OS (p=0.035) 27.9 months vs 16.9 months. ORR 40.4% vs 25.6%. - December 13, 2019.
Oraxol
Metastatic breast cancer
Clinical trials to commence 2019.
Oral Eribulin
Phase 1/2 initiation announced November 26, 2018.
Oraxol and pembrolizumab (Keytruda)
Solid Tumors
Phase 1 poster at ASCO June 1, 2019.
Oratecan (ASCO 2019)
Solid Tumors
Phase 1 preliminary data released May 3, 2019. 3/7 complete responses.
Oraxol
Angiosarcoma

Latest News

  1. Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

    The agreement covers China, Hong Kong and Macao (the "Territory") and represents an expansion of the existing relationship between the two companies. Athenex will receive payments of up to $200 million which include an

  2. Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer

    First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial Data to be presented today in an oral presentation at the 2019 San Antonio Breast

  3. Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019

    BUFFALO, N.Y., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  4. Athenex Announces $60 Million Private Placement

    BUFFALO, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  5. Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium

    Abstract selected for the SABCS press programOral presentation of Oral Paclitaxel and encequidar Phase III results on December 13Company to host a Key Opinion Leader webcast event for the investment community BUFFALO,

  6. Athenex, Inc. Announces Third Quarter 2019 Financial Results

    Oral presentation of Phase III Oral Paclitaxel data at the San Antonio Breast Cancer Symposium NDA submissions for Oral Paclitaxel and tirbanibulin ointment are on track $19.2 million of product sales in Q3 2019, a 45%

  7. Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma

    BUFFALO, N.Y., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  8. Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment

    BUFFALO, N.Y., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  9. Athenex Completes Construction of New API Facility in Chongqing

    BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  10. Athenex to Present at the 2019 San Antonio Breast Cancer Symposium

    BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  11. Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

    BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  12. Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

    BUFFALO, N.Y., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  13. Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy

    BUFFALO, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of